Pharmaceuticals: US Generic Growth to Stay, Selective on Structural Play
The pharmaceutical sector, emerging from the volatility of the past two post-pandemic and geopolitically tumultuous years, is now on a recovery...
224 Views
Sun Pharma Industries - One-Time Costs Hit Earnings
Adjusting for exceptional items (Rs39,358mn), Sun Pharma’s 4QFY22 net earnings (Rs15,821mn) was slightly lower than expectations
190 Views
Sun Pharma: Strong Performance on All Fronts; Specialty Buoyed
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general...
165 Views
Domestic Formulation / US (ex-Taro) on steady footing
Sun Pharma (SUNP) delivered yet another robust quarterly performance, with the beat on margins led by Domestic Formulation (DF) / Emerging Markets...
79 Views
Reaping the fruits of enhanced efforts in Specialty
After having toughed out for more than three years in the US, its flagship product Ilumya is continuously ramping-up sales, with Cequa also showing...
190 Views